Bristol Myers Squibb, Janssen Move Closer To Phase 3 For Blood Thinner Candidate

Bristol Myers Squibb & Co BMY and Johnson & Johnson's JNJ unit Janssen Pharmaceuticals Inc announced results from the Phase 2 AXIOMATIC-TKR study of Factor XIa inhibitor called milvexian.
Milvexian (BMS-986177) significantly lowered patients' rate of venous thromboembolism (VTE) after knee surgery compared to the commonly used anticoagulant enoxaparin, without increasing the risk of infection bleeding.
At daily doses of at least 100 mg, those treated with milvexian saw significantly lower VTE rates than enoxaparin.
A group of patients receiving the highest once-daily dose (200mg) of milvexian saw a 7% VTE rate, compared to a 21% rate for the group of patients who took 40 mg of enoxaparin.
While the study tested both single and twice-daily doses of milvexian, the companies will wait to see the results from another Phase 2 trial in secondary stroke before deciding on a regimen.
That readout is expected in 1H of 2022. There were no major bleeds in the milvexian arm compared to one in the enoxaparin arm.
The major plus clinically relevant non-major bleeds (CRNM) rates were 0.8% and 1.4% in the milvexian and enoxaparin arms, respectively.
Price Action: BMY shares are up 0.43% at $59.69, and JNJ shares are down 0.55% at $164.10 during the market session on the last check Monday.